ClinicalTrials.gg
RecruitingNCT06090539Updated Oct 23, 2026

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

A Phase 1/2 interventional study of BMS-986458 and Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma, sponsored by Bristol-Myers Squibb. Recruiting at 76 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 10 months later.
Updated Oct 23, 20262 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb — 2 open to participants now, 5 under way, none of them phase 3. Lymphoma, Non-Hodgkin · Bristol-Myers Squibb.

Planned enrollment
2nd of 46
460 · median 58
Started
2023
with 2 others
Phase 1/2
9 of 50
1 open now
Registered
48th of 50
by date

Among the 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb, this one is the 2nd largest by planned enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2023, is one of 9 in phase 1/2, and was the 48th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

2 of the 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.

03

Conditions studied

  • Relapsed/Refractory Non-Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants ≥ 18 years of age with frontline or R/R NHL.
  • Participant must have (defined by at least one FDG-avid lesion for FDG-avid disease and one bi-dimensionally measurable disease on cross sectional imaging by computed tomography or magnetic resonance imaging with at least one lesion > 1.5 cm in the transverse diameter).
  • Participants must accept and follow pregnancy prevention plan.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have an (ECOG) performance status ≥ 2.
  • Participants with an inability to comply with listed restrictions, precautions and prohibited treatments.
  • Participants must not have prior CAR-T, or radiotherapy ≤ 4 weeks, systemic anticancer treatment ≤ 5 half-lives or 4 weeks, SCT ≤ 6 months (only applicable to BMS-986458 single agent or rituximab combination cohorts), or autologous SCT ≤ 3 months prior to study intervention initiation.
  • In BMS-986458 + T-cell engager combination cohorts: Participants must not have prior alloSCT or solid organ transplantation, history of confirmed progressive multifocal leukoencephalopathy (PML); known or suspected history of hemophagocytic lymphohistiocytosis (HLH); known or suspected chronic active Epstein-Barr (EBV) infection.
  • Participants must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable risk if participating in this study.
  • Participants must not have known or suspected central nervous system involvement.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
460 participants (estimated)

Study arms

  • Experimental
    Part A1

    Single Agent

    Drug: BMS-986458

  • Experimental
    Part A2

    Combination Treatment

    Drug: BMS-986458 · Drug: Rituximab · Drug: Glofitamab/Obinutuzumab · Drug: Mosunetuzumab

  • Experimental
    Part B1

    Single Agent

    Drug: BMS-986458

  • Experimental
    Part B2

    Combination Treatment

    Drug: BMS-986458 · Drug: Rituximab · Drug: Glofitamab/Obinutuzumab · Drug: Epcoritamab · Drug: Golcadomide

  • Experimental
    Part B3

    Single Agent

    Drug: BMS-986458

Interventions

  • DrugBMS-986458

    Specified dose on specified days.

  • Specified dose on specified days.

    Also known as: Truxima

  • DrugGlofitamab/Obinutuzumab

    Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

    Also known as: GEN3013, Epkinly, Tepkinly

  • Specified dose on specified days

    Also known as: BMS-986369, CC-99282

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 2 years and 1 month

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 2 years and 1 month

  3. Number of participants with AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria

    Time frame: Up to Day 28

  4. Number of participants with AEs leading to death

    Time frame: Up to 2 years and 1 month

  5. Number of participants with AEs leading to discontinuation

    Time frame: Up to 2 years and 1 month

  6. Number of participants with a complete response rate (CRR) according to the Lugano response criteria for Non-Hodgkin Lymphoma by Investigator assessment

    Part B2 Cohort B only

    Time frame: Up to 2 years and 11 month

Secondary outcomes

  1. Maximum concentration (Cmax)

    Time frame: Up to 4 months

  2. Time of maximum concentration (Tmax)

    Time frame: Up to 4 months

  3. Area under the plasma concentration-time curve within a dosing interval [AUC(TAU)]

    Time frame: Up to 4 months

  4. Number of participants with a complete response rate (CRR) according to the Lugano response criteria for Non-Hodgkin Lymphoma by Investigator assessment

    Time frame: Up to 2 years

  5. Number of participants with an overall response rate (ORR) according to the Lugano response criteria for Non-Hodgkin Lymphoma by investigator assessment

    Time frame: Up to 2 years

  6. Duration of response (DOR)

    Time frame: Up to 3 years

  7. Time to response (TTR)

    Time frame: Up to 3 years

  8. Progression-free survival (PFS)

    Time frame: Up to 3 years

  9. Overall survival (OS)

    Time frame: Up to 3 years

07

Study locations

35 of 76 sites recruiting
  • Mayo Clinic in Arizona - Phoenix
    Phoenix, Arizona 85054, United States
    Recruiting
    • Allison Rosenthal, Site 0067 · Contact
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
    Recruiting
    • Alex Herrera, Site 0020 · Contact626-218-2405
  • Local Institution - 0068
    Jacksonville, Florida 32224, United States
    Not yet recruiting
    • Site 0068 · Contact
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Recruiting
    • Bijal Shah, Site 0027 · Contact813-745-4294
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
    • David Qualls, Site 0044 · Contact617-632-6844
  • Mayo Clinic in Rochester, Minnesota
    Rochester, Minnesota 55905, United States
    Recruiting
    • Yucai Wang, Site 0066 · Contact
  • Local Institution - 0124
    Omaha, Nebraska 68105, United States
    Not yet recruiting
    • Site 0124 · Contact
  • Local Institution - 0047
    Lake Success, New York 11042, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0037
    New York, New York 10016, United States
    Not yet recruiting
    • Site 0037 · Contact
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Jennifer Lue, Site 0046 · Contact917-887-8514
  • Local Institution - 0045
    Providence, Rhode Island 02903, United States
    Not yet recruiting
    • Site 0045 · Contact
  • Local Institution - 0118
    Antofagasta, AN 1240000, Chile
    Not yet recruiting
    • Site 0118 · Contact
  • Local Institution - 0105
    Santiago, Metropolitana de Santiago 7580206, Chile
    Not yet recruiting
    • Site 0105 · Contact
  • Local Institution - 0109
    Santiago, Santiago Metropolitan 8420383, Chile
    Not yet recruiting
    • Site 0109 · Contact
  • Beijing Cancer hospital
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • Yuqin Song, Site 0088 · Contact13683398726
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510555, China
    Recruiting
    • Qingqing Cai, Site 0084 · Contact13798101121
  • Local Institution - 0087
    Zhengzhou, Henan 450008, China
    Not yet recruiting
    • Site 0087 · Contact
  • Local Institution - 0120
    Suzhou, Jiangsu 215006, China
    Not yet recruiting
    • Site 0120 · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
    • Fei Li, Site 0089 · Contact13970038386
  • Local Institution - 0130
    Nanchang, Jiangxi 330029, China
    Not yet recruiting
    • Site 0130 · Contact
  • Local Institution - 0129
    Shenyang, Liaoning 110001, China
    Not yet recruiting
    • Site 0129 · Contact
  • Local Institution - 0132
    Qingdao, Shandong 266003, China
    Not yet recruiting
    • Site 0132 · Contact
  • Local Institution - 0131
    Shanghai, Shanghai Municipality 0, China
    Not yet recruiting
    • Site 0131 · Contact
  • Local Institution - 0128
    Hangzhou, Zhejiang 310003, China
    Not yet recruiting
    • Site 0128 · Contact
  • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
    Bordeaux, Aquitaine 33076, France
    Recruiting
    • Fontanet Bijou, Site 0057 · Contact33556333333
  • Local Institution - 0125
    Lyon, Nan 69373, France
    Not yet recruiting
    • Site 0125 · Contact
  • Hopital Claude Huriez - CHU de Lille
    Lille, Nord 59000, France
    Recruiting
    • Franck Morschhauser, Site 0003 · Contact33320445713
  • Gustave Roussy
    Villejuif, Paris 94800, France
    Recruiting
    • Vincent Ribrag, Site 0001 · Contact33142114507
  • Henri Mondor Hospital
    Créteil, Val-de-Marne 94010, France
    Recruiting
    • François LEMONNIER, Site 0059 · Contact+33145178242
  • CHU SAINT ELOI - Departement Hematologie Clinique
    Montpellier, 34295, France
    Recruiting
    • Guillaume Cartron, Site 0005 · Contact+33675926918
  • Hôpital Saint-Louis
    Paris, 75010, France
    Recruiting
    • Catherine Thieblemont, Site 0058 · Contact33142499236
  • Institut Claudius Regaud
    Toulouse, 31059, France
    Recruiting
    • Loïc Ysebaert, Site 0002 · Contact33531156351
  • Universitätsklinikum Münster - Albert Schweitzer Campus
    Münster, North Rhine-Westphalia 48149, Germany
    Recruiting
    • Evgenii Shumilov, Site 0049 · Contact+492518357765
  • Universitaetsklinikum des Saarlandes
    Homburg, Saarland 66424, Germany
    Recruiting
    • Joerg Bittenbring, Site 0050 · Contact4968411615000
  • Universitätsklinikum Leipzig
    Leipzig, Saxony 04103, Germany
    Recruiting
    • Vladan Vucinic, Site 0029 · Contact493419713841
  • Helios Klinikum Berlin-Buch
    Berlin, 13125, Germany
    Recruiting
    • Snjezana Janjetovic, Site 0051 · Contact+49 30 9401-12104
  • Universitaetsklinikum Essen
    Essen, 45122, Germany
    Recruiting
    • Bastian von Tresckow, Site 0070 · Contact+491631751277
  • Local Institution - 0103
    Pátrai, Achaḯa 26504, Greece
    Not yet recruiting
    • Site 0103 · Contact
  • Local Institution - 0107
    Athens, 10676, Greece
    Not yet recruiting
    • Site 0107 · Contact
  • Local Institution - 0102
    Athens, 11 527, Greece
    Not yet recruiting
    • Site 0102 · Contact
  • Local Institution - 0119
    Hong Kong, 0, Hong Kong
    Not yet recruiting
    • Site 0119 · Contact
  • Local Institution - 0094
    Bologna, 40138, Italy
    Not yet recruiting
    • Site 0094 · Contact
  • Local Institution - 0116
    Brescia, 25123, Italy
    Not yet recruiting
    • Site 0116 · Contact
  • Local Institution - 0098
    Milan, 20132, Italy
    Not yet recruiting
    • Site 0098 · Contact
  • Local Institution - 0113
    Milan, 20133, Italy
    Not yet recruiting
    • Site 0113 · Contact
  • Local Institution - 0112
    Pisa, 56126, Italy
    Not yet recruiting
    • Site 0112 · Contact
  • Local Institution - 0111
    Ravenna, 48121, Italy
    Not yet recruiting
    • Site 0111 · Contact
  • Local Institution - 0115
    Roma, 00144, Italy
    Not yet recruiting
    • Site 0115 · Contact
  • Local Institution - 0110
    Roma, 00168, Italy
    Not yet recruiting
    • Site 0110 · Contact
  • Local Institution - 0097
    Verona, 37134, Italy
    Not yet recruiting
    • Site 0097 · Contact
  • Local Institution - 0090
    Nagoya, Aichi-ken 4668560, Japan
    Not yet recruiting
    • Site 0090 · Contact
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
    Recruiting
    • Wataru Munakata, Site 0091 · Contact81335422511
  • University of Yamanashi Hospital
    Chūō, Yamanashi 4093898, Japan
    Recruiting
    • Ichiro Kawashima, Site 0086 · Contact0552731111
  • Kyushu University Hospital
    Fukuoka, 812-8582, Japan
    Recruiting
    • Kohta Miyawaki, Site 0092 · Contact81926425230
  • Maastricht UMC+
    Maastricht, Limburg 6229 HX, Netherlands
    Recruiting
    • Marjolein Van der Poel, Site 0052 · Contact+31433877026
  • Local Institution - 0121
    Amsterdam, North Holland 1981 HV, Netherlands
    Not yet recruiting
    • Site 0121 · Contact
  • University Medical Center Groningen
    Groningen, 9713 GZ, Netherlands
    Recruiting
    • Marcel Nijland, Site 0053 · Contact050-3616161
  • Local Institution - 0077
    Seoul, Seoul Teugbyeolsi 06351, South Korea
    Not yet recruiting
    • Site 0077 · Contact
  • Local Institution - 0123
    Seoul, Seoul-teukbyeolsi [Seoul] 03080, South Korea
    Not yet recruiting
    • Site 0123 · Contact
  • Local Institution - 0078
    Seoul, Seoul-teukbyeolsi 05505, South Korea
    Not yet recruiting
    • Site 0078 · Contact
  • Hospital Universitario Virgen de la Victoria
    Málaga, Andalusia 29010, Spain
    Recruiting
    • Antonio Rueda Dominguez, Site 0007 · Contact607847416
  • Hospital Universitari Vall d'Hebron
    Barcelona, Barcelona [Barcelona] 08035, Spain
    Recruiting
    • Pau Abrisqueta Costa, Site 0041 · Contact34932746000X4975
  • Hospital General Universitario Gregorio Marañon
    Madrid, Madrid, Comunidad de 28009, Spain
    Recruiting
    • Mariana Bastos Oreiro, Site 0069 · Contact34915868394
  • Clinica Universidad de Navarra
    Pamplona, Navarre 31008, Spain
    Recruiting
    • Miguel Canales Albendea, Site 0018 · Contact34 948 396 297
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
    Recruiting
    • Daniel Morillo Giles, Site 0006 · Contact349155048002218
  • Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca
    Salamanca, 37007, Spain
    Recruiting
    • Alejandro Martin García-Sancho, Site 0019 · Contact34923291100
  • Ospedale Regionale Bellinzona e Valli
    Bellinzona, Canton Ticino 6500, Switzerland
    Recruiting
    • Anastasios Stathis, Site 0033 · Contact41918118931
  • University Hospital Basel
    Basel, 4031, Switzerland
    Recruiting
    • Fatime Krasniqi, Site 0032 · Contact41612655074
  • Hopitaux Universitaires de Geneve (HUG)
    Geneva, 1205, Switzerland
    Recruiting
    • Noemie Lang, Site 0048 · Contact+41795532406
  • Local Institution - 0096
    Ankara, 06170, Turkey (Türkiye)
    Not yet recruiting
    • Site 0096 · Contact
  • Local Institution - 0101
    Ankara, 06620, Turkey (Türkiye)
    Not yet recruiting
    • Site 0101 · Contact
  • Local Institution - 0099
    Istanbul, 34365, Turkey (Türkiye)
    Not yet recruiting
    • Site 0099 · Contact
  • Local Institution - 0122
    Istanbul, 34899, Turkey (Türkiye)
    Not yet recruiting
    • Site 0122 · Contact
  • Local Institution - 0071
    Southampton, Hampshire SO16 0YD, United Kingdom
    Not yet recruiting
    • Site 0071 · Contact
  • Local Institution - 0081
    Manchester, Lancashire M20 4BX, United Kingdom
    Not yet recruiting
    • Site 0081 · Contact
  • Local Institution - 0072
    Edinburgh, Midlothian EH4 2XU, United Kingdom
    Not yet recruiting
    • Site 0072 · Contact
08

References and documents

Publications

  • Mortensen DS, Shunatona HP, Holmberg-Douglas N, Rhodes J, Da Silva D, Gamez J, Groza M, Zhu J, Christoforou A, Johnson SA, Khambatta G, Narla RK, Nimje RY, Huang D, Dodd DS, Griffin J, Miseo G, Whitefield B, Weiss DR, Rader J, Kuzu E, Leisten J, Lai C, Shi L, Del Rosario J, Dalvie D, Rolfe M, Zapf CW, Belmont P, Alexander M, Bence N, Groocock L. Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin Lymphoma. J Med Chem. 2026 Feb 26;69(4):4424-4438. doi: 10.1021/acs.jmedchem.5c03123. Epub 2026 Feb 11. PubMed 41670385 ↗

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Oct 2027, 45 months after the start.

Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's planned 45 months is below that.

Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2023
First posted
Oct 19, 2023
StartActual
Dec 29, 2023
Primary completionEst.
Oct 28, 2027
CompletionEst.
Oct 28, 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (2 China)
  • Sun Yat-sen University Cancer Center · Guangzhou, China
  • Local Institution - 0132 · Qingdao, China
Show 1 removed
  • Local Institution - 0084 · Guangzhou, China
Oct 23, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Universitätsklinikum Münster - Albert Schweitzer Campus · Münster, GermanyContact •••6010→•••7765
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    2 sites added, 1 site removed
    Show 2 added (2 China)
    • Sun Yat-sen University Cancer Center · Guangzhou, China
    • Local Institution - 0132 · Qingdao, China
    Show 1 removed
    • Local Institution - 0084 · Guangzhou, China
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Universitätsklinikum Münster - Albert Schweitzer Campus · Münster, GermanyContact •••6010→•••7765
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06090539
Responsible party
Sponsor
First posted
Oct 19, 2023
Start date
Dec 29, 2023
Primary completion
Oct 28, 2027 (estimated)
Completion
Oct 28, 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion